Details
Stereochemistry | ACHIRAL |
Molecular Formula | C27H44O2 |
Molecular Weight | 400.6371 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 3 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)=CCC\C(C)=C\CC\C(C)=C\CCC(=O)OC\C=C(/C)CCC=C(C)C
InChI
InChIKey=ZPACYDRSPFRDHO-ROBAGEODSA-N
InChI=1S/C27H44O2/c1-22(2)12-8-14-24(5)16-10-17-25(6)18-11-19-27(28)29-21-20-26(7)15-9-13-23(3)4/h12-13,16,18,20H,8-11,14-15,17,19,21H2,1-7H3/b24-16+,25-18+,26-20+
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/18560615Curator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/4452287
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18560615
Curator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/4452287
Gefarnate is a drug used for the treatment of gastric ulcers. It also has been proposed for use in the treatment of dry eye syndrome, although for this disease it was discontinued in 2008. The mechanism of action consists of the normalisation of the mucous secretion, followed by the restoration of the normal defensive mucous barrier.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0070257 Sources: http://www.ncbi.nlm.nih.gov/pubmed/4452287 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/4452287
treatment: 600 mg daily by mouth for 30 days
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/9464189
For the studies in vitro, cultured rat cornea sections (3 mm diameter) were incubated with radiolabeled sodium sulfate, rinsed, and then incubated for 30 min in the presence of the drug. Gefarnate significantly increased the mucin-like glycoprotein secretion from cultured rat corneas
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
A02BX07
Created by
admin on Fri Dec 15 15:25:59 GMT 2023 , Edited by admin on Fri Dec 15 15:25:59 GMT 2023
|
||
|
WHO-VATC |
QA02BX07
Created by
admin on Fri Dec 15 15:25:59 GMT 2023 , Edited by admin on Fri Dec 15 15:25:59 GMT 2023
|
||
|
NCI_THESAURUS |
C29698
Created by
admin on Fri Dec 15 15:25:59 GMT 2023 , Edited by admin on Fri Dec 15 15:25:59 GMT 2023
|
||
|
WHO-VATC |
QA02BX77
Created by
admin on Fri Dec 15 15:25:59 GMT 2023 , Edited by admin on Fri Dec 15 15:25:59 GMT 2023
|
||
|
WHO-ATC |
A02BX77
Created by
admin on Fri Dec 15 15:25:59 GMT 2023 , Edited by admin on Fri Dec 15 15:25:59 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C73187
Created by
admin on Fri Dec 15 15:25:59 GMT 2023 , Edited by admin on Fri Dec 15 15:25:59 GMT 2023
|
PRIMARY | |||
|
200-121-0
Created by
admin on Fri Dec 15 15:25:59 GMT 2023 , Edited by admin on Fri Dec 15 15:25:59 GMT 2023
|
PRIMARY | |||
|
DTXSID0048636
Created by
admin on Fri Dec 15 15:25:59 GMT 2023 , Edited by admin on Fri Dec 15 15:25:59 GMT 2023
|
PRIMARY | |||
|
1ISE2Y6ULA
Created by
admin on Fri Dec 15 15:25:59 GMT 2023 , Edited by admin on Fri Dec 15 15:25:59 GMT 2023
|
PRIMARY | |||
|
100000084519
Created by
admin on Fri Dec 15 15:25:59 GMT 2023 , Edited by admin on Fri Dec 15 15:25:59 GMT 2023
|
PRIMARY | |||
|
D005778
Created by
admin on Fri Dec 15 15:25:59 GMT 2023 , Edited by admin on Fri Dec 15 15:25:59 GMT 2023
|
PRIMARY | |||
|
SUB07889MIG
Created by
admin on Fri Dec 15 15:25:59 GMT 2023 , Edited by admin on Fri Dec 15 15:25:59 GMT 2023
|
PRIMARY | |||
|
CHEMBL2105085
Created by
admin on Fri Dec 15 15:25:59 GMT 2023 , Edited by admin on Fri Dec 15 15:25:59 GMT 2023
|
PRIMARY | |||
|
5282182
Created by
admin on Fri Dec 15 15:25:59 GMT 2023 , Edited by admin on Fri Dec 15 15:25:59 GMT 2023
|
PRIMARY | |||
|
1546
Created by
admin on Fri Dec 15 15:25:59 GMT 2023 , Edited by admin on Fri Dec 15 15:25:59 GMT 2023
|
PRIMARY | |||
|
DB12079
Created by
admin on Fri Dec 15 15:25:59 GMT 2023 , Edited by admin on Fri Dec 15 15:25:59 GMT 2023
|
PRIMARY | |||
|
m5681
Created by
admin on Fri Dec 15 15:25:59 GMT 2023 , Edited by admin on Fri Dec 15 15:25:59 GMT 2023
|
PRIMARY | Merck Index | ||
|
Gefarnate
Created by
admin on Fri Dec 15 15:25:59 GMT 2023 , Edited by admin on Fri Dec 15 15:25:59 GMT 2023
|
PRIMARY | |||
|
1281
Created by
admin on Fri Dec 15 15:25:59 GMT 2023 , Edited by admin on Fri Dec 15 15:25:59 GMT 2023
|
PRIMARY | |||
|
51-77-4
Created by
admin on Fri Dec 15 15:25:59 GMT 2023 , Edited by admin on Fri Dec 15 15:25:59 GMT 2023
|
PRIMARY |
ACTIVE MOIETY